AstraZeneca starts new study into Ovarian cancer

AstraZeneca has announced enrolment of the first patient in the Phase III clinical programme for olaparib, an oral poly ADP ribose polymerase (PARP) inhibitor being investigated for the treatment of BRCA mutated ovarian cancer.  The Phase III SOLO (Study of OLaparib in Ovarian cancer) programme is designed to determine the benefit, by progression-free survival, of olaparib as a maintenance monotherapy in BRCA mutated ovarian cancer patients.  The SOLO 1 study is being conducted in collaboration with the Gynecologic Oncology Group and the SOLO 2 study with the European Network of Gynaecological Oncological Trial Groups. Both trials are randomised, double blind,